UK Regulator Approves 2nd COVID-19 Antibody Treatmenton December 2, 2021 at 2:28 pm

The UK’s medicines regulator on Thursday approved an antibody treatment for COVID-19, the disease caused by the CCP virus. Xevudy (sotrovimab), developed by GlaxoSmithKline (GSK) and Vir Biotechnology, is the second monoclonal antibody treatment approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) after it approved Lagevrio (molnupiravir) last month. The drug is administered by intravenous infusion over 30 minutes, and it is approved for people aged 12 and over and weighing more than 40 kg (88 pounds). It’s authorised for use in people who have mild to moderate CCP (Chinese Communist Party) virus infection and at least one risk factor for developing severe illness, such as obesity, older age (55 years and over), diabetes mellitus, or heart disease. MHRA said one dose of the single monoclonal antibody was found in a clinical trial to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic CCP virus infection. The agency recommended …

Leave a Reply

Your email address will not be published.

Next Post

South African Medical Association Chair: Omicron Cases ‘Extremely Mild’ So Far-Tammy Hung

Thu Dec 2 , 2021
The chair of the South African Medical Association, Dr. Angelique Coetzee, said that symptoms of Omicron have been mild so far and can be treated at home. “The majority of what we are presenting to primary health care practitioners are extremely mild cases, so mild to moderate. And so, these patients, […]

Chief Editor

Johny Watshon

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Quick Links

Newsletter Signup

Sign up now and never miss a thing!

You're Signed Up!

Now that you are signed up, we will send you exclusive offers periodically.